Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101)

被引：0
|
作者：
Masafumi Yamaguchi
Hirohito Tada
Tetsuya Mitsudomi
Takashi Seto
Kohei Yokoi
Nobuyuki Katakami
Kazuhiko Nakagawa
Makoto Oda
Mitsunori Ohta
Toshiyuki Sawa
Motohiro Yamashita
Norihiko Iked
Hideo Saka
Masahiko Higashiyama
Hiroaki Nomori
Hiroshi Semba
Shunichi Negoro
Yasutaka Chiba
Mototsugu Shimokawa
Masahiro Fukuoka
Yoichi Nakanishi
机构：
[1] National Hospital Organization Kyushu Cancer Center,Department of Thoracic Oncology
[2] Osaka City General Hospital,Department of Thoracic Surgery
[3] Aichi Cancer Center,Department of Thoracic Surgery
[4] Nagoya University School of Medicine,Department of Thoracic Surgery
[5] Kobe City Medical Center General Hospital,Division of Pulmonary Medicine
[6] Kinki University School of Medicine,Department of Medical Oncology
[7] Kanazawa University School of Medicine,Department of Thoracic Surgery
[8] Osaka Habikino Medical Center,Department of Thoracic Surgery
[9] Gifu Municipal Hospital,Department of Pulmonary Medicine
[10] National Hospital Organization Shikoku Cancer Center,Department of Thoracic Surgery
[11] Tokyo Medical University,Department of Surgery
[12] National Hospital Organization Nagoya Hospital,Department of Pulmonary Medicine
[13] Osaka International Cancer Institute,Department of General Thoracic Surgery
[14] Kumamoto University,Department of Thoracic Surgery, School of Medicine
[15] Kumamoto Regional Medical Center,Division of Respiratory Disease
[16] Hyogo Cancer Center,Department of Medical Oncology
[17] Kinki University School of Medicine,Division of Biostatistics, Clinical Research Center
[18] Yamaguchi University School of Medicine,Department of Biostatistics
[19] Kyushu University,Research Institute for Diseases of the Chest
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Gemcitabine; Uracil-tegafur; Adjuvant chemotherapy; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2216 / 2223
页数：7
相关论文
共 50 条
  • [21] A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer
    Toyooka, Shinichi
    Okumura, Norihito
    Nakamura, Hiroshige
    Nakata, Masao
    Yamashita, Motohiro
    Tada, Hirohito
    Kajiwara, Shinsuke
    Watanabe, Naoki
    Okada, Morihito
    Sakamoto, Junichi
    Aoe, Motoi
    Soh, Junichi
    Miyoshi, Shinichiro
    Hotta, Katsuyuki
    Matsuo, Keitaro
    Date, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : 699 - 706
  • [22] A Phase III Study of Adjuvant Chemotherapy in Patients with Completely Resected, Node-Negative Non-Small Cell Lung Cancer
    Kunitoh, H.
    Sakurai, H.
    Tsuboi, M.
    Wakabayashi, M.
    Okada, M.
    Suzuki, K.
    Ikeda, N.
    Takahama, M.
    Takenoyama, M.
    Ohde, Y.
    Yoshiya, K.
    Matsumoto, I.
    Yamashita, M.
    Marutsuka, T.
    Date, H.
    Hasumi, T.
    Yamashita, Y.
    Okumura, N.
    Watanabe, S.
    Asamura, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S270 - S271
  • [23] Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
    Lee, Kuan-Yu
    Hsu, Chen-Xiong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 647 - 648
  • [24] ADJUVANT CHEMOTHERAPY IN RESECTED STAGE IB-III NON SMALL CELL LUNG CANCER
    Zhang, B.
    Wong, H-L
    Gunawardana, D.
    Parente, P.
    de Boer, R.
    Barling, A.
    Antippa, P.
    Wong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S32 - S32
  • [25] Adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer
    Wang, S.
    Ou, W.
    Sun, H.
    Yang, H.
    Ye, X.
    Fang, Q.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.
    Calvo, Virginia
    Domine, Manuel
    Sullivan, Ivana
    Gonzalez-Larriba, Jose-Luis
    Ortega, Ana Laura
    Bernabe, Reyes
    Sala, Maria Angeles
    Campos, Begona
    De Castro, Javier
    Martin-Martorell, Paloma
    Bosch-Barrera, Joaquim
    Mielgo, Xabier
    Vila, Laia
    Casal, Joaquin
    Ros, Silver
    Aguillo, Maite Martinez
    Padilla, Airam
    Sandiego, Sergio
    Machado, Jonathan Aires
    Provencio-Pulla, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Is adjuvant radiochemotherapy superior to postoperative radiotherapy alone in patients with completely resected stage II or IIIA non-small cell lung cancer?
    Baumann, M
    STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (04) : 220 - 221
  • [28] Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010)
    Kenmotsu, Hirotsugu
    Sugawara, Shunichi
    Watanabe, Yasutaka
    Saito, Haruhiro
    Okada, Morihito
    Chen-Yoshikawa, Toyofumi Fengshi
    Ohe, Yuichiro
    Nishio, Wataru
    Nakagawa, Shizuka
    Nagao, Haruka
    CANCER SCIENCE, 2022, 113 (12) : 4327 - 4338
  • [29] Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer
    Nakagawa, K.
    Tada, H.
    Akashi, A.
    Yasumitsu, T.
    Iuchi, K.
    Taki, T.
    Kodama, K.
    BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 817 - 821
  • [30] A feasibility study of adjuvant carboplatin (C) plus gemcitabine (G) in completely resected stage IB-III non-small-cell lung cancer (NSCLC)
    Horiike, A.
    Ohyanagi, F.
    Okano, Y.
    Satoh, Y.
    Okumura, S.
    Ishikawa, Y.
    Nakagawa, K.
    Horai, T.
    Nishio, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345